Biomarin Pharmaceutical Inc (BMRN) concluded trading on Thursday at a closing price of $61.25, with 2.91 million shares of worth about $178.38 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -27.65% during that period and on January 16, 2025 the price saw a loss of about -0.54%. Currently the company’s common shares owned by public are about 190.55M shares, out of which, 188.22M shares are available for trading.
Stock saw a price change of -10.43% in past 5 days and over the past one month there was a price change of -7.21%. Year-to-date (YTD), BMRN shares are showing a performance of -6.82% which decreased to -34.46% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $61.15 but also hit the highest price of $94.85 during that period. The average intraday trading volume for Biomarin Pharmaceutical Inc shares is 1.47 million. The stock is currently trading -7.07% below its 20-day simple moving average (SMA20), while that difference is down -6.60% for SMA50 and it goes to -20.72% lower than SMA200.
Biomarin Pharmaceutical Inc (NASDAQ: BMRN) currently have 190.55M outstanding shares and institutions hold larger chunk of about 96.90% of that.
The stock has a current market capitalization of $11.67B and its 3Y-monthly beta is at 0.29. PE ratio of stock for trailing 12 months is 36.88, while it has posted earnings per share of $1.66 in the same period. Its PEG reads 1.84 and has Quick Ratio of 2.62 while making debt-to-equity ratio of 0.11. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BMRN, volatility over the week remained 3.77% while standing at 2.83% over the month.
Stock’s fiscal year EPS is expected to rise by 159.44% while it is estimated to increase by 42.60% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wolfe Research on November 15, 2024 offering an Outperform rating for the stock and assigned a target price of $95 to it. On October 10, 2024, Raymond James Resumed their recommendations, while on August 20, 2024, Bernstein Upgrade their ratings for the stock with a price target of $110. Stock get a Neutral rating from Robert W. Baird on May 17, 2024.
